Vital3D Talks Shaping the Future of Medicine With Organ Bioprinting

The use of 3D bioprinting in regenerative medicine continues to grow. More and more companies are developing their own additive manufacturing solutions to create organs and tissues tailored to the needs of individual patients. With this in mind, biotech company Vital3D offers advanced solutions for medical research, drug discovery and regenerative medicine. The aim? To integrate cutting-edge 3D bioprinting technologies (such as two-photon polymerization) that will shape the future of medicine through personalized patient treatment. We spoke to the company’s CEO to find out more about its manufacturing systems and his vision of the current state of 3D printing in the healthcare sector.

3DN: Could you introduce yourself and tell us about your connection with 3D printing?

My name is Vidmantas Sakalys and I’m the CEO of Vital3D Technologies. With a background in computer engineering, I have over 20 years’ practical experience in the management of various IT companies. Later, fate decided to give me the chance to get to know the laser microfabrication industry, and I’ve now been working in the field of photonic innovations for over 10 years. Lasers are very effective for 3D printing models that require very high precision. So it was my knowledge of laser manufacturing that led me to the field of 3D bioprinting.

Vidmantas Sakalys, CEO of Vital3D

3DN: Could you tell us about Vital3D?

Vital3D is a pioneering Lithuanian-based biotech company dedicated to innovating advanced solutions in medical research, drug discovery and regenerative medicine. Founded in 2021, Vital3D’s team of experts has introduced innovative bioprinting technology aimed at bridging the gap between organ supply and demand, specializing in the 3D printing of human organs, in particular the kidney. With a staff of 10, we have experts in lasers, biotechnology, software programming and mechanical engineering.